A Randomized, Phase 1, Open-Label Study in Healthy HIV-Negative Women to Evaluate the Pharmacokinetics, Safety and Bleeding Patterns Associated with 90-Day Use of Matrix Vaginal Rings Containing 200 mg Dapivirine and 320 mg

IPM, which was acquired by the Population Council in 2022, is the developer of the dapivirine vaginal ring and a multipurpose prevention technology (MPT) vaginal ring containing dapivirine and levonorgestrel. Two Phase 1 trials, evaluating pharmacokinetics, safety, bleeding patterns, acceptability, adherence and the vaginal microenvironment of the dapivirine levonorgestrel ring were conducted at sites in the United States by the Microbicide Trials Network (MTN). The data sets shared here support the bleeding and acceptability analyses from one of the clinical trials (MTN-044).